With the introduction of modern treatment, the incidence of SCD in myocardial infarction (MI) survivors may decline in parallel with coronary heart disease, especially in patients receiving optimal medical therapy (ß-blockers, aspirin, statins, and angiotensin-converting enzyme [ACE] inhibitors) and revascularization [15-16]. The gene discussed is ACE; the disease is myocardial infarction.